Evidence map›Paper›PMID 32415541›Full record

ArticleEuropean journal of epidemiology2021

Antipsychotic use in dementia: the relationship between neuropsychiatric symptom profiles and adverse outcomes.

Christoph Mueller, Christeena John, Gayan Perera, Dag Aarsland, Clive Ballard, Robert Stewart

Open access · hybridAbstract read
In one paragraph

Article in European journal of epidemiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 5 pooled it
4.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 5 syntheses or guidelines pooled it, 49 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 2 countries.

Christoph MuellerKing's College London, Institute of Psychiatry, Psychology and Neuroscience, De Crespigny Park, London, UK. christoph.mueller@kcl.ac.uk.ORCID http://orcid.org/0000-0001-9816-1686
Christeena JohnKing's College London, Institute of Psychiatry, Psychology and Neuroscience, De Crespigny Park, London, UK.
Gayan PereraKing's College London, Institute of Psychiatry, Psychology and Neuroscience, De Crespigny Park, London, UK.
Dag AarslandKing's College London, Institute of Psychiatry, Psychology and Neuroscience, De Crespigny Park, London, UK.
Clive BallardKing's College London, Institute of Psychiatry, Psychology and Neuroscience, De Crespigny Park, London, UK.
Robert StewartKing's College London, Institute of Psychiatry, Psychology and Neuroscience, De Crespigny Park, London, UK.
King's College London · GB

Funding

Medical Research Council MC_PC_17214Medical Research Council MR/T045302/1
6 · The paper itself

Abstract

Antipsychotic treatments are associated with safety concerns in people with dementia. The authors aimed to investigate whether risk of adverse outcomes related to antipsychotic prescribing differed according to major neuropsychiatric syndromes-specifically psychosis, agitation, or a combination. A cohort of 10,106 patients with a diagnosis of dementia was assembled from a large dementia care database in South East London. Neuropsychiatric symptoms closest to first dementia diagnosis were determined according to the Health of the Nation Outcome Scales' mental and behavioural problem scores and the sample was divided into four groups: 'agitation and psychosis', 'agitation, but no psychosis', 'psychosis, but no agitation', and 'neither psychosis nor agitation'. Antipsychotic prescription in a one-year window around first dementia diagnosis was ascertained as exposure variable through natural language processing from free text. Cox regression models were used to analyse associations of antipsychotic prescription with all-cause and stroke-specific mortality, emergency hospitalisation and hospitalised stroke adjusting for sixteen potential confounders including demographics, cognition, functioning, as well as physical and mental health. Only in the group 'psychosis, but no agitation' (n = 579), 30% of whom were prescribed an antipsychotic, a significant antipsychotic-associated increased risk of hospitalised stroke was present after adjustment (adjusted hazard ratio (HR) 2.16; 95% confidence interval (CI) 1.09-4.25). An increased antipsychotic-related all-cause (adjusted HR 1.14; 95% CI 1.04-1.24) and stroke-specific mortality risk (adjusted HR 1.28; 95% CI 1.01-1.63) was detected in the whole sample, but no interaction between the strata and antipsychotic-related mortality. In conclusion, the adverse effects of antipsychotics in dementia are complex. Stroke risk may be highest when used in patients presenting with psychosis without agitation, indicating the need for novel interventions for this group.

Indexed as

AgedAged, 80 and overAntipsychotic AgentsBehavioral SymptomsDementiaFemaleHumansLondonMaleMortalityPsychomotor AgitationPsychotic DisordersStrokeTreatment OutcomeAntipsychotic AgentsAntipsychoticsDementiaMortalityPrognosisRisk stratificationStroke

Identifiers

PMID32415541
PMCPMC7847435
OpenAlexW3024506838

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.